Synonyms: LY 210448 | LY-210448
dapoxetine is an approved drug (UK (2008))
Compound class:
Synthetic organic
Comment: Dapoxetine hydrochloride (PubChem CID 71352) is the component used in marketed formulations.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: dapoxetine |
|
No information available. |
Summary of Clinical Use ![]() |
Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI), for the treatment of premature ejaculation [4]. This drug is not approved by the US FDA. National approval agencies in countries including Austria, Germany, Argentina, Mexico, New Zealand, Finland, Italy and Portugal have granted marketing authorisation. In the UK dapoxetine hydrochloride, with brand name Priligy, has been available since 2008. A Phase 3 clinical trial in the US, NCT00211094, has been completed but approval has still not been granted. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Dapoxetine inhibits the serotonin transporter SERT (SLC6A4) [2-3], acting centrally to inhibit the ejaculatory expulsion reflex [1]. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) |